Eli Lilly and Company (LLY) — closed signal from April 24, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on July 23, 2026.
Predicted vs. what happened
LLY price · publication thesis → realized outcomesplit-adjusted
$875.00 – $900.00Entry zone — fair-value band
$890.84Published — price the day we called it
$1,006.64Target — the price the thesis aimed for
$1,249.45Peak — highest point inside the window, not a realized return
$1,185.87Window close — end-of-window price, context only
What happened
Target reached
Reached its target in 19 days.
Peak price
$1,249.45
peak on July 7, 2026 — not a realized returnPeak gain
+40.3%
peak, from the publication priceWindow close
$1,185.87
end-of-window price, context onlyDays to target
19
Window
April 24, 2026 – July 23, 2026
The thesis — published April 24, 2026
Predicted growth
+13%
over the measurement windowTarget price
$1,006.64
the price the thesis aimed forEntry zone
$875.00 – $900.00
the fair-value band we waited forPrice at publication
$890.84
published April 24, 2026Confidence
77%
how strongly the data lined upTimeframe
Short-term (0–3 months)
Eli Lilly looks well positioned for the next quarter because its business is still growing while the stock has cooled from earlier strength. New LillyDirect updates help the sales and distribution picture, and the recent price dip gives a clearer base for a rebound. Healthcare leaders like Lilly often hold up when markets get shaky.
Primary drivers
- Strong drug franchises continue to drive sales and profits
- LillyDirect news improves how products reach customers
- The pullback gives a more orderly timing for recovery
- Healthcare leaders can be steadier during market stress
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Lyra
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.